Today we celebrate one of our favourite clinical trials - ENZAMET! It is 10 years since ENZAMET opened and beyond its pivotal data establishing that adding enzalutamide to ADT improves survival for mHSPC patients, it continues to produce a very strong stream of high-quality findings that affect our practice today. ENZAMET also straddled an epochal era which included the advent of doectaxel upfront in mHSPC, and the introduction of PSMA PET/CT.
Today we were very happy to speak to two of the principal architects of ENZAMET; Professor Ian Davis, Chair of the ANZUP co-operative trials group, and Professor Chris Sweeney. Director of the South Australian ImmunoGENomics Cancer Institute, who told us the extraordinary story of how this trial came about, the challenges and evolutions of its rollout, and the strong tail end of translational and other research which it continues to produce. It is a great example of how investigator initiated trials run by nimble and ambitious cooperative trial groups like ANZUP can do things a little differently.

This is a Themed Podcast supported by our Gold Partners, Astellas.

Een better on our YouTube channel

Links:
ANZUP
Previous podcast from #ANZUP24 Annual Scientific Meeting
ENZAMET 2019 paper NEJM
ENZAMET 2023 paper Lancet Oncology